FDG-PET/CT in the diagnosis of recurrent breast cancer

2012 ◽  
Vol 53 (1) ◽  
pp. 12-16 ◽  
Author(s):  
Ryusuke Murakami ◽  
Shin-ichiro Kumita ◽  
Tamiko Yoshida ◽  
Keiichi Ishihara ◽  
Tomonari Kiriyama ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Predictive Value ◽  
Cancer Recurrence ◽  
Final Diagnosis ◽  
Recurrent Breast Cancer ◽  
Whole Body ◽  
Positron Emission ◽  
Pet Ct ◽  
The Difference ◽  
Recurrent Breast

Background An advantage of PET/CT has been demonstrated for diagnosis of several tumor entities. In patients with breast cancer, early diagnosis and accurate restaging of recurrence after surgery is important for selection of the most appropriate therapeutic strategy. Purpose To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using 18F-fluorodeoxyglucose (FDG), for follow-up of patients with suspected recurrent breast cancer. Material and Methods Forty-seven patients with suspected recurrent breast cancer underwent PET/CT. The PET and PET/CT images were interpreted without knowledge of the results of other diagnostic modalities, and compared with each other with reference to the final diagnosis. Results Twenty-five (53%) patients suffered tumor recurrence. The overall sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET/CT were 96%, 91%, 92%, 95%, and 94%, respectively. In comparison with PET, PET/CT had a higher sensitivity and accuracy (96% vs. 80% and 94% vs. 81%, respectively). The difference in diagnostic accuracy between PET/CT and PET was significant ( P < 0.05). Conclusion The present findings indicate that PET/CT is an accurate, sensitive and reliable modality for screening and detection of breast cancer recurrence. PET/CT appears to be an effective surveillance tool, as it is able to cover the whole body in a single procedure and shows good performance.

Diagnosis of recurrent breast cancer: 18F-FDG PET/TAC as first choice

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10681-10681
Author(s):  
M. Mion ◽  
F. Chierichetti ◽  
G. Liessi ◽  
S. Bissoli ◽  
E. Milan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Scintigraphy ◽  
Final Diagnosis ◽  
Recurrent Breast Cancer ◽  
Whole Body ◽  
Ct Scans ◽  
Bone Lesions ◽  
First Choice ◽  
Pet Ct ◽  
Recurrent Breast

10681 Background: we began using PET diagnosis in 1994 and since the beginning of 2000 we started with a PET/CT system. Aim of our study was to evaluate if this new imaging modality may be the first step in the detection of recurrence in patients with a history of breast tumors. Methods: we reviewed retrospectively 22 patients (mean age 60, range 46–76 years) already treated for a breast cancer. A total of 32 PET/CT scans were performed (repeated in 10 patients). All patients were submitted to other examinations, such as bone scintigraphy and liver ecography, but also mammography and CT scan. Results: 14/32 PET/CT were negative for recurrence in 10 patients (4 scans as a second one). In a mean follow up of 10 months, 1 case is not yet clear: in presence of relevant increase of Ca15.3 (up to 176 ng/ml) the first scan was negative and the second one evidentiated a pattern of lung inflammation. Among the other 13/14 negative scans, 3 patients presented ambiguous/positive bone scintigraphy for metastases, not assessed at the final diagnosis. 18/32 PET/CT scans were positive for local recurrence or distant metastases. Among these positive cases, a patient with normal bone scintigraphy presented a mild uptake of FDG in the right omerus. The second scan (5 months later) showed focal increased uptake of FDG in the same bone site, not evident in the CT images, and many small lung nodules, 1–2 mm size. In 3 patients PET localized muliple bone lesions, in 2 CT was completely normal. Finally, 1 out of the 18 positive results was false positive: a patients with a single lung nodule (1.5 cm) was submitted to surgery and the final diagnosis was benign lesion. PET/CT was crucial for the patient’s management in 19 out of 22 patients. Conclusions: recurrent breast cancer is generally characterized by multiple sites of metastases and few cases take advantage of surgical resection. In our group of 22 patients just 2 out of them received surgery (for local relapse and lung metastases). Therefore, in most cases a whole body examination, like PET/CT may be more useful respect to other modalities to assess how spread is the recurrence. Further data are needed but, in our preliminary experience, PET/CT seems to be the first choice to evaluate patients with previous breast cancer. No significant financial relationships to disclose.

Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer

2016 ◽  
Vol 85 (2) ◽  
pp. 459-465 ◽  
Author(s):  
Lino M. Sawicki ◽  
Johannes Grueneisen ◽  
Benedikt M. Schaarschmidt ◽  
Christian Buchbender ◽  
James Nagarajah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Recurrent Breast Cancer ◽  
Whole Body ◽  
Pet Ct ◽  
Recurrent Breast ◽  
Fdg Pet Ct

scholarly journals Texture Analysis in the Diagnosis of Primary Breast Cancer: Comparison of High-Resolution Dedicated Breast Positron Emission Tomography (dbPET) and Whole-Body PET/CT

2020 ◽  
Vol 7 ◽  
Author(s):  
Yoko Satoh ◽  
Kenji Hirata ◽  
Daiki Tamada ◽  
Satoshi Funayama ◽  
Hiroshi Onishi
Keyword(s):  
Breast Cancer ◽  
Positron Emission Tomography ◽  
High Resolution ◽  
Texture Analysis ◽  
Texture Features ◽  
Emission Tomography ◽  
Whole Body ◽  
Tumor Characteristics ◽  
Positron Emission ◽  
Pet Ct

Objective: This retrospective study aimed to compare the ability to classify tumor characteristics of breast cancer (BC) of positron emission tomography (PET)-derived texture features between dedicated breast PET (dbPET) and whole-body PET/computed tomography (CT).Methods: Forty-four BCs scanned by both high-resolution ring-shaped dbPET and whole-body PET/CT were analyzed. The primary BC was extracted with a standardized uptake value (SUV) threshold segmentation method. On both dbPET and PET/CT images, 38 texture features were computed; their ability to classify tumor characteristics such as tumor (T)-category, lymph node (N)-category, molecular subtype, and Ki67 levels was compared. The texture features were evaluated using univariate and multivariate analyses following principal component analysis (PCA). AUC values were used to evaluate the diagnostic power of the computed texture features to classify BC characteristics.Results: Some texture features of dbPET and PET/CT were different between Tis-1 and T2-4 and between Luminal A and other groups, respectively. No association with texture features was found in the N-category or Ki67 level. In contrast, receiver-operating characteristic analysis using texture features' principal components showed that the AUC for classification of any BC characteristics were equally good for both dbPET and whole-body PET/CT.Conclusions: PET-based texture analysis of dbPET and whole-body PET/CT may have equally good classification power for BC.

Postchemotherapy rheumatism.

1993 ◽  
Vol 11 (4) ◽  
pp. 768-770 ◽  
Author(s):  
C L Loprinzi ◽  
J Duffy ◽  
J N Ingle
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Combination Chemotherapy ◽  
Case Reports ◽  
Cancer Recurrence ◽  
Recurrent Breast Cancer ◽  
Rheumatologic Diseases ◽  
Clinical Phenomenon ◽  
Recurrent Breast

PURPOSE This report describes a previously unreported clinical phenomenon that occurs in some patients after completion of combination chemotherapy. METHODS AND RESULTS Eight case reports are presented. Affected patients developed a syndrome of myalgias/arthralgias within several months of completing cyclophosphamide/fluorouracil (5FU)-containing adjuvant combination chemotherapy for breast cancer. These symptoms did not appear to be related to cancer recurrence or any common rheumatologic disorder. The syndrome generally resolved over several months. CONCLUSION Postchemotherapy rheumatism is a syndrome of myalgias/arthralgias that usually develops 1 to 3 months after completion of adjuvant chemotherapy. Recognition of this syndrome can limit the need for extensive work-ups to exclude recurrent breast cancer or inflammatory rheumatologic diseases.

scholarly journals Diagnostic Value of 18F-FDG-PET/CT in Patients with FUO

2020 ◽  
Vol 9 (7) ◽  
pp. 2112
Author(s):  
Stamata Georga ◽  
Paraskevi Exadaktylou ◽  
Ioannis Petrou ◽  
Dimitrios Katsampoukas ◽  
Vasilios Mpalaris ◽  
...  
Keyword(s):  
Predictive Value ◽  
Fdg Pet ◽  
Final Diagnosis ◽  
Diagnostic Value ◽  
Whole Body ◽  
Considerable Proportion ◽  
Clinical Criteria ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Conventional diagnostic imaging is often ineffective in revealing the underlying cause in a considerable proportion of patients with fever of unknown origin (FUO). The aim of this study was to assess the diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in patients with FUO. We retrospectively reviewed 18F-FDG-PET/CT scans performed on 50 consecutive adult patients referred to our department for further investigation of classic FUO. Final diagnosis was based on histopathological and microbiological findings, clinical criteria, or clinical follow-up. Final diagnosis was established in 39/50 (78%) of the patients. The cause of FUO was infection in 20/50 (40%), noninfectious inflammatory diseases in 11/50 (22%), and malignancy in 8/50 (16%) patients. Fever remained unexplained in 11/50 (22%) patients. 18F-FDG-PET/CT scan substantially contributed to the diagnosis in 70% of the patients, either by identifying the underlying cause of FUO or by directing to the most appropriate site for biopsy. Sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of 18F-FDG-PET/CT for active disease detection in patients with FUO were 94.7%, 50.0%, 84.0%, 85.7%, and 75.0%, respectively. In conclusion, whole-body 18F-FDG-PET/CT is a highly sensitive method for detection of the underlining cause of FUO or for correctly targeting suspicious lesions for further evaluation.

scholarly journals Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
B. B. Koolen ◽  
W. V. Vogel ◽  
M. J. T. F. D. Vrancken Peeters ◽  
C. E. Loo ◽  
E. J. Th. Rutgers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Malignant Tumors ◽  
Volume Effect ◽  
Whole Body ◽  
Response Monitoring ◽  
Breast Cancer Patients ◽  
Dedicated Breast Pet ◽  
Positron Emission ◽  
Pet Ct ◽  
Elevated Glucose

Positron emission tomography (PET), with or without integrated computed tomography (CT), using 18F-fluorodeoxyglucose (FDG) is based on the principle of elevated glucose metabolism in malignant tumors, and its use in breast cancer patients is frequently being investigated. It has been shown useful for classification, staging, and response monitoring, both in primary and recurrent disease. However, because of the partial volume effect and limited resolution of most whole-body PET scanners, sensitivity for the visualization of small tumors is generally low. To improve the detection and quantification of primary breast tumors with FDG PET, several dedicated breast PET devices have been developed. In this nonsystematic review, we shortly summarize the value of whole-body PET/CT in breast cancer and provide an overview of currently available dedicated breast PETs.

scholarly journals FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Andrea Gombos ◽  
David Venet ◽  
Lieveke Ameye ◽  
Peter Vuylsteke ◽  
Patrick Neven ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Positron Emission Tomography Imaging ◽  
Metastatic Breast ◽  
Endocrine Treatment ◽  
Luminal Breast Cancer ◽  
Positron Emission ◽  
Pet Ct ◽  
The Difference ◽  
Fdg Pet Ct

AbstractBiomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing 18F-FDG-PET/CT non-response (n = 45) and ctDNA detection (n = 46) after 14 days of exemestane-everolimus (EXE-EVE) to identify MBC patients who will not benefit. The metabolic non-response rate was 66.6%. Median PFS in non-responding patients (using as cut-off 25% for SUVmax decrease) was 3.1 months compared to 6.0 months in those showing response (HR: 0.77, 95% CI: 0.40–1.50, p = 0.44). The difference was significant when using a “post-hoc” cut-off of 15% (PFS 2.2 months vs 6.4 months). ctDNA detection at D14 was associated with PFS: 2.1 months vs 5.0 months (HR-2.5, 95% CI: 1.3–5.0, p = 0.012). Detection of ctDNA and/or the absence of 18F-FDG-PET/CT response after 14 days of EXE-EVE identifies patients with a low probability of benefiting from treatment. Independent validation is needed.

Sign in / Sign up

Export Citation Format

Share Document